YR001 (ApicHope Pharmaceutical Group)

YR001 is a small molecule drug candidate being developed by Apichope Pharmaceutical for the treatment of cardiovascular and cerebrovascular diseases. Formulated as an orally disintegrating tablet (ODT), YR001 is designed to improve patient convenience and adherence, particularly for patients who may have difficulty swallowing conventional tablets. The drug is currently in the preclinical stage of development and utilizes Apichope's specialized drug delivery technology. While the specific active pharmaceutical ingredient and molecular target have not been publicly disclosed, the candidate is a key part of Apichope's pipeline of value-added medicines, which often focus on improved formulations of established therapeutic agents.

Other names

YR001 orally disintegrating tabletYR-001 orally disintegrating tabletYR 001 orally disintegrating tabletYR001 ODTYR-001 ODTYR 001 ODT